Pharma · Biopharma
Congress and KOL sponsorship showed no measurable return.
This marketing & margin audit identified $88k in wasted annual spend in a Pharma business, evidenced, senior reviewed, and delivered in 7 days.
The business
A biopharma company invested six figures a year in medical congresses and KOL sponsorships, a long standing part of how it engaged the scientific and prescribing community. The spend was considered essential to presence and relationships, so it renewed each year without being tied to any measurable outcome in share of voice or prescribing behavior.
What triggered the audit
The congress and KOL budget was substantial and renewed automatically, yet nobody could point to a measurable return from it. The audit attempted to connect the sponsorship and congress spend to any attributable outcome, share of voice, engagement or prescribing lift, testing whether the investment produced anything trackable.
What the audit found
The congress and KOL spend had no measurable return anyone could trace. When the audit tried to connect it to share of voice, meaningful engagement or prescribing outcomes, there was no instrumentation and no attributable link, the investment renewed on the belief that presence mattered, not on evidence that it worked. A share of the spend genuinely supported important scientific relationships, but a large portion funded congresses and sponsorships with no follow up, no lead capture and no way to know whether they influenced anything. Because it was habitual, six figure and unmeasured, the waste was invisible. Redirecting the unaccountable portion toward measurable medical engagement was worth roughly $88k a year.
What we changed
Cut the congress and KOL spend with no attributable outcome, and shifted it toward measurable medical engagement activity that can be tracked.
Instrumented the sponsorships that were retained against share of voice and engagement, so future spend is justified by real evidence.
Required every congress and KOL investment to carry a defined, trackable objective before it is funded rather than renewed on habit.
Made medical engagement return a monitored metric, so six figure spend can never again renew purely on the belief that presence matters.
The result
The published chart shows congress spend with a tracked return rising from 8% to 88%, an 80 percentage point increase. That is measurement coverage, not evidence that previously unmeasured sponsorship produced no return; the annual figure is budget redirected into measurable activity. $88k a year redirected from unmeasurable congress and KOL spend into engagement that can actually be tracked, an annual figure equal to 15× the $5,950 Audit + Sprint fee, one of the largest leaks we found. For any biopharma or events heavy brand, habit is the trap: six figure sponsorships renew on the belief that presence matters, with no measurable return. If your congress spend has no attributable outcome, much of it is running on faith. A fixed fee audit tests it in days, so presence is justified by evidence, not tradition.
From kickoff to signed off findings: 7 days, inside our fixed 5–7 day window.
What the client said
$88k a year of wasted spend cut in 7 days
Congress spend with a tracked return: 8% → 88%
“Six figures a year in congresses and KOL sponsorships, renewed on habit. Leslie tried to connect it to share of voice, engagement or prescribing and found no instrumentation at all. The unmeasurable part now funds engagement we can track.”
Leslie MartinSenior Auditor · signed this audit off